A patient with a large, 12cm symptomatic desmoid tumor experienced significant spontaneous regression to 3cm while on active surveillance. This challenges the common assumption that only small tumors shrink on their own, highlighting the disease's unpredictability even in severe cases.

As more effective treatments for desmoid tumors become available, a critical unmet need is emerging: knowing when to stop therapy. Future research must focus on identifying signals, such as radiologic changes on MRI, to guide treatment duration. This will help clinicians avoid both the risk of early relapse from stopping too soon and the toxicity of unnecessary overtreatment.

For desmoid tumors, systemic therapy is typically paused after 1 to 1.5 years once the tumor stabilizes and stops shrinking. Unlike many other treatments, it can be stopped abruptly without needing to taper the dose, simplifying the discontinuation process for patients and clinicians.

Desmoid tumors exhibit highly variable behavior, acting as a chronic disease in some patients while being manageable in others. This necessitates a personalized, long-term treatment strategy rather than a standard protocol, often requiring a diverse armamentarium of therapeutic options to be used over a patient's lifetime as needs change.

Desmoid tumors can shrink without treatment, a phenomenon seen in up to 35% of patients under observation. This inherent biological behavior makes it difficult to prove that continued tumor reduction during long-term therapy is solely due to the drug's effect.

The standard of care for desmoid tumors has shifted away from upfront surgery due to high recurrence rates and poor patient outcomes. Experts now recommend systemic or other local therapies first, reserving surgery only for emergencies or after careful multidisciplinary team review.

Unlike traditional oncology where the goal is complete eradication, stable residual masses on imaging after successful desmoid tumor treatment are common and acceptable. Clinicians should not be compelled to operate or change therapy based on this finding alone, as it does not indicate active disease.

Once the primary treatment, surgery for desmoid tumors has fallen out of favor. Even with successful operations, recurrence rates can be as high as 70% within months. This has prompted a major shift towards systemic therapies and observation as first-line management.

Treatment algorithms for desmoid tumors are highly dependent on tumor location. While medical therapy is preferred for mesenteric or head and neck tumors to avoid morbidity, surgery remains a viable first-line option for the specific case of abdominal wall tumors.